We compared PFS and OS between the four groups and found that high-risk MDS patients with lower caspase-3 showed significantly worse outcomes than the other groups, followed by low-risk MDS patients with higher caspase-3 and low-risk MDS patients with lower caspase-3 levels (Figure 8A,B). This evidence concerns the gene CASP3 and myelodysplastic syndrome.